McKesson (MCK)
(Delayed Data from NYSE)
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.
Walgreens (WBA), Village MD Plan to Expand Into New Hampshire
by Zacks Equity Research
Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.
Align Technology (ALGN) Debuts Latest Feature for ClinCheck
by Zacks Equity Research
Align Technology's (ALGN) CBCT integration feature for ClinCheck will enable doctors to treat a broader range of cases with the Invisalign clear aligners.
Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.
Here's Why You Should Hold on to Insulet (PODD) Stock For Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and robust segmental performance.
Exact Sciences (EXAS) Cologuard Sales Up but Costs Rise
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.
Boston Scientific (BSX) Hurt by Price and Volume Issues
by Zacks Equity Research
The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.
DexCom (DXCM) to Boost Diabetes Management With New Approval
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) booming vaccine business and diverse product lines.
Here's Why You Should Hold on to Medtronic (MDT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $284.85, marking a +1.29% move from the previous day.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Here's Why You Should Hold NextGen (NXGN) Stock For Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario
by Zacks Equity Research
Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.
Myriad Genetics (MYGN) to Offer Companion Diagnostic for Lynparza
by Zacks Equity Research
Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.
Here's Why You Should Retain Illumina (ILMN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) better-than-expected results and strategic collaborations.
Here's Why You Should Hold Onto Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.